Foreign Data: Sintilimab’s Development Shows What Not To Do When Pursuing US Approval

 
• By Sue Sutter
Tennis racket
Innovent and Lilly seemingly committed some unforced errors in how they conducted the ORIENT trial and brought the results to the US FDA. • Source: Alamy

More from United States

More from North America